Canine immunoglobulin F(ab')2 fragments protect cats against feline parvovirus virus infection

pH-responsive multi-network composite cellulose-based hydrogels for stable delivery of oral IgY-Fab fragments

Yolk immunoglobulin (IgY) is perfect supplement to mammalian immunoglobulin G in passive immune protection but with poor delivery stability. This work succeeded in pH-responsive oral delivery of IgY-Fab fragments with cellulose based multi-network composite hydrogels. Data displayed that the hydrogel 2 showed superior mechanical properties and load performance (encapsulation efficiency of 99.25% and loading capacity of 45.11 mg/100 mg). The stability of the released Fab was confirmed by HPLC with Fab purity up to 79.65% at the end of digestion. The FTIR spectra revealed the potential interactions between Fab and the hydrogel matrix of the formation of hydrogen bonds or electrostatic interactions between the groups of -OH, -CH2, and -COO-. The excellent rehydration of the hydrogels wouldn't be impacted by low-temperature freeze drying. In sum, this work is of great significance to the development of Fab-themed health-care food, intensive processing of poultry eggs and the economic construction of related industries.

Towards the Antiviral Agents and Nanotechnology-Enabled Approaches Against Parvovirus B19

Parvovirus B19 (B19V) as a human pathogenic virus, would cause a wide range of clinical manifestations. Besides the supportive and symptomatic treatments, the only FDA-approved antiviral drug for the treatment of B19V is intravenous immunoglobulins, which however, have limited efficacy and high cost. By far, there are still no virus-specific therapeutics clinically available to treat B19V infection. Therefore, exploiting the potential targets with a deep understanding of the life cycle of B19V, are pivotal to the development of B19V-tailored effective antiviral approaches. This review will introduce antiviral agents via blocking viral invasion, inhibiting the enzymes or regulatory proteins involved in DNA synthesis, and so on. Moreover, nanotechnology-enabled approaches against B19V will also be outlined and discussed through a multidisciplinary perspective involving virology, nanotechnology, medicine, pharmaceutics, chemistry, materials science, and other fields. Lastly, the prospects of the antiviral agents and nanosystems in terms of fabrication, clinical translation and potential breakthroughs will be briefly discussed.